AIMS: Traditional management of advanced @entity43 is surgical debulking followed by chemotherapy; however, there is an increasing tendency for neoadjuvant chemotherapy followed by surgery. The morphology of @entity43 following chemotherapy often differs markedly from native @entity5 . This study aimed to compare the immunophenotype of post-chemotherapy @entity43 with that of untreated @entity5 . METHODS: Post-chemotherapy @entity43 (n = 16) were stained with a range of antibodies. In six cases, pre-chemotherapy core biopsies were also stained; all were high-grade serous @entity189 . Antibodies used in the study were @entity5822 , @entity10224 , @entity8587 , ER, PR, @entity876 , @entity986 , @entity4206 and @entity1758 . RESULTS: In eight post-treatment cases, there was minimal or no morphological response to chemotherapy, and in eight there was a significant response (in two additional cases, no @entity5 was identified). All pre-chemotherapy biopsies showed diffuse positivity of the @entity5 cells with @entity5822 , @entity10224 and @entity8587 . ER, @entity876 and @entity986 were diffusely positive in five, four and three cases respectively. One case was focally PR positive, and all were @entity4206 negative. @entity1758 staining was high; all but one case exhibited a proliferation index of >60%. Post-chemotherapy @entity5 exhibited a similar immunophenotype: diffuse positivity with @entity5822 in all cases and with @entity10224 , @entity8587 , ER, @entity876 and @entity986 in the majority, an immunophenotype in keeping with a @entity189 . All were negative with @entity4206 , and all but two with PR. The @entity1758 proliferation index was lower in those cases exhibiting a significant morphological response, and @entity876 was less likely to be positive in cases with minimal or no response. CONCLUSIONS: The immunophenotype of post-chemotherapy @entity43 is very similar to that of native untreated @entity5 , illustrating that @entity5822 , @entity10224 , @entity8587 , ER, @entity876 and @entity986 may be of value in identifying @entity5 cells and in subtyping the @entity5 if a pre-chemotherapy biopsy has not been obtained.

An immunohistochemical and morphological analysis of post-chemotherapy XXXX .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinomas', 'ovarian carcinoma'] @entity986 :: ('1029', 'Gene') :: ['p16'] @entity5 :: ('MESH:D009369', 'Disease') :: ['residual tumour', 'tumours', 'neoplasm', 'tumour'] @entity4206 :: ('8626', 'Gene') :: ['p63'] @entity189 :: ('MESH:D002277', 'Disease') :: ['serous carcinoma', 'carcinomas'] @entity1758 :: ('57534', 'Gene') :: ['MIB1'] @entity8587 :: ('7490', 'Gene') :: ['WT1'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity5822 :: ('3855', 'Gene') :: ['CK7'] @entity10224 :: ('94025', 'Gene') :: ['CA125']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian carcinoma']
